Patents and Postapproval Batch Testing - Can postapproval FDA filings immunize pharma companies from patent lawsuits? - BioPharm International

ADVERTISEMENT

Patents and Postapproval Batch Testing
Can postapproval FDA filings immunize pharma companies from patent lawsuits?


BioPharm International
Volume 25, Issue 12, pp. 55-56

REFERENCES

1. Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661, 669-71 (1990).

2. 35 U.S.C. 271(e)(1) (2012).

3. 659 F.3d 1057, 1060, 1070 (Fed. Cir. 2011).

4. Ibid. at 1060.

5. Ibid. at 1070-72.

6. Ibid. at 1070.

7. 686 F.3d 1348 (Fed. Cir. 2012).

8. Ibid. at 1351.

9. Ibid. at 1353.

10. Ibid. at 1352-53.

11. Ibid. at 1354-55.

12. Ibid. at 1361-76.

13. Ibid. at 1357-58.

14. Petition for a Writ of Certiorari at i., GlaxoSmithKline v. Classen Immunotherapies, Inc., No. 11-1078 (U.S. Feb. 28, 2012).

15. Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193, 206-07 (2005); Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA Releases REMS Report
September 25, 2014
NIH Funds Tissue Chip for Drug Screening
September 25, 2014
Author Guidelines
Source: BioPharm International,
Click here